Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

https://doi.org/10.1182/blood-2019-127881

Published: 2019

Journal Articles

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Mark van Duin, Annemiek Broijl, Jasper Koenders, Sonja Zweegman, Monique C. Minnema, Francois G. Kavelaars, Remco Hoogenboezem, Kazem Nasserinejad, Mario Boccadoro, Peter Valk, PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 1798.

https://doi.org/10.1182/blood-2019-130086

Published: 2019

Journal Articles

Allele-Specific Expression of GATA2 in AML with CEBPA Biallelic Mutations

Roger Mulet-Lazaro, MSc, Stanley van Herk, B.Sc., Claudia Erpelinck-Verschueren, B.Sc., Mathijs A. Sanders, PhD MSc, Eric Bindels, PhD, Peter Valk, PhD, Michael Rehli, PhD, Claudia Gebhard, PhD, Ruud Delwel, PhD, B.J. Wouters

Blood (2019) 134 (Supplement_1): 1235.

https://doi.org/10.1182/blood-2019-129766

Published: 2019

Journal Articles

Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia

Blood (2019) 134 (Supplement_1): 5166.

https://doi.org/10.1182/blood-2019-131595

Published: 2019

Journal Articles

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Blood (2019) 134 (Supplement_1): 2719.

https://doi.org/10.1182/blood-2019-131211

Published: 2019

Journal Articles

Whole Transcriptome RNA Sequencing As a Comprehensive Diagnostic Tool for Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 2762.

https://doi.org/10.1182/blood-2018-99-111115

Published: 2018

Journal Articles

Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression

Sophie Ottema, MSc, Roger Mulet-Lazaro, B.Sc., Berna Beverloo, PhD, Marije Havermans, Ir, Claudia Erpelinck-Verschueren, B.Sc., Tim Grob, MD, Peter Valk, PhD, Eric Bindels, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD, Leonie Smeenk, PhD, Ruud Delwel, PhD

Blood (2018) 132 (Supplement 1): 2766.

https://doi.org/10.1182/blood-2018-99-113339

Published: 2018

Journal Articles

A Leukemic Progression Model of Severe Congenital Neutropenia Uncovers a Novel Mechanism of AML Development Involving Elevated Inflammatory Responses, Mutation of CXXC4 and Decreased TET2 Levels

Patricia Olofsen, MSc, Szabolcs Fatrai, PhD, Paulette van Strien, BSc, Julia Obenauer, MSc, Remco Hoogenboezem, MSc, Claudia Erpelinck-Verschueren, B.Sc., Onno Roovers, BSc, Torsten Haferlach, MD, Peter Valk, PhD, Rebekka Schneider, MDPhD, Emma De Pater, PhD, Ivo Touw, PhD

Blood (2018) 132 (Supplement 1): 540.

https://doi.org/10.1182/blood-2018-99-115914

Published: 2018

Journal Articles

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Blood (2018) 132 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2018-99-115370

Published: 2018

Journal Articles

Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression

Blood (2018) 132 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2018-99-115068

Published: 2018

Journal Articles

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Peter Valk, PhD

Blood (2016) 128 (22): SCI-30.

https://doi.org/10.1182/blood.V128.22.SCI-30.SCI-30

Published: 2016

Journal Articles

The Impact of Novel Molecular Markers on Risk Stratification in Acute Myeloid Leukemia

Bob Löwenberg, MD, PhD, Peter Valk, PhD, Ivo P. Touw, PhD, Ruud Delwel, PhD

Blood (2012) 120 (21): SCI-33.

https://doi.org/10.1182/blood.V120.21.SCI-33.SCI-33

Published: 2012

Journal Articles

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

Hendrik JM de Jonge, Peter Valk, PhD, Kim R Kampen, Arja ter Elst, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD, C. Michel Zwaan, MD, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, Willem A. Kamps, MD, PhD, Ruud Delwel, PhD, Bob Lowenberg, MD, PhD, Eveline S de Bont, MD, PhD

Blood (2009) 114 (22): 997.

https://doi.org/10.1182/blood.V114.22.997.997

Published: 2009

Journal Articles

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

Wendy Deenik, MD, Bronno van der Holt, PhD, Jeroen JWM Janssen, MD, Isabel W.T. Chu, Peter Valk, PhD, Gert Ossenkoppele, MD, PhD, Ilse van der Heiden, Pieter Sonneveld, MD, PhD, Ron van Schaik, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 2208.

https://doi.org/10.1182/blood.V114.22.2208.2208

Published: 2009

Journal Articles

Mutant Wilms’ Tumor 1 ( WT1 ) mRNA with Premature Termination Codons Is Sensitive to Nonsense-Mediated RNA Decay in Acute Myeloid Leukemia (AML)

Saman Abbas, Claudia Erpelinck, Chantal Goudswaard, B. Lowenberg, MD, Peter Valk, PhD

Blood (2008) 112 (11): 2538.

https://doi.org/10.1182/blood.V112.11.2538.2538

Published: 2008

Journal Articles

Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes.

Maria E. Figueroa, MD, Bas J. Wouters, MD, Yushan Li, Peter Valk, PhD, Bob Lowenberg, MD, PhD, Ari M. Melnick, MD, Ruud Delwel, PhD

Blood (2007) 110 (11): 2117.

https://doi.org/10.1182/blood.V110.11.2117.2117

Published: 2007

Journal Articles

Myeloproliferative Disease in the Pathogenesis and Survival of Budd-Chiari Syndrome.

Jasper H. Smalberg, Sarwa D. Murad, MD, Eric Braakman, PhD, Peter Valk, PhD, Mies C. Kappers-Klunne, MD, Harry L. Janssen, MD, Frank W.G. Leebeek, MD

Blood (2006) 108 (11): 1480.

https://doi.org/10.1182/blood.V108.11.1480.1480

Published: 2006

Journal Articles

Predictive Value of Gene Expression with Respect to IgVH Mutational Status and Survival in Chronic Lymphocytic Leukemia.

Mars B. Van’t Veer, PhD, Anne Brooymans, Anton W. Langerak, PhD, Wilfried J. Graveland, Kirsten Van Lom, PhD, Peter Valk, PhD

Blood (2004) 104 (11): 1913.

https://doi.org/10.1182/blood.V104.11.1913.1913

Published: 2004

Journal Articles

High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabin.

Jan J. Cornelissen, MD, PhD, Peter Valk, PhD, Gregor E.G. Verhoef, MD, PhD, Wim M. Smit, MD, PhD, Marinus van Marwijk-Kooij, MD, PhD, Shulamit Wittebol, MD, Marinus H.J. van Oers, MD, PhD, Hanneke C. Kluin-Nelemans, MD, PhD, Bob Lowenberg, MD, PhD, Roelof Willemze, MD, PhD, Antonius V.M.B. Schattenberg, MD, PhD, Gert Ossenkoppele, MD, PhD

Blood (2004) 104 (11): 19.

https://doi.org/10.1182/blood.V104.11.19.19

Published: 2004

NARROW

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Allele-Specific Expression of GATA2 in AML with CEBPA Biallelic Mutations

Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Whole Transcriptome RNA Sequencing As a Comprehensive Diagnostic Tool for Acute Myeloid Leukemia

Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression

A Leukemic Progression Model of Severe Congenital Neutropenia Uncovers a Novel Mechanism of AML Development Involving Elevated Inflammatory Responses, Mutation of CXXC4 and Decreased TET2 Levels

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

The Impact of Novel Molecular Markers on Risk Stratification in Acute Myeloid Leukemia

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

Mutant Wilms’ Tumor 1 ( WT1 ) mRNA with Premature Termination Codons Is Sensitive to Nonsense-Mediated RNA Decay in Acute Myeloid Leukemia (AML)

Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes.

Myeloproliferative Disease in the Pathogenesis and Survival of Budd-Chiari Syndrome.

Predictive Value of Gene Expression with Respect to IgVH Mutational Status and Survival in Chronic Lymphocytic Leukemia.

High Rates of Molecular Response and Low Incidence of Mutations in Patients Treated with Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated with a Dose-Escalated Combination of Imatinib and Cytarabin.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only